GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

GSK (NYSE:GSK) announced Friday that its asthma therapy Nucala (mepolizumab) reached the main goal in a Phase 3 trial for patients with chronic obstructive pulmonary disease (COPD), a common lung ...

GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala ...

GSK has also filed Nucala with the FDA as a treatment for COPD. Analyst GlobalData forecasts that Nucala could be the leading anti-eosinophilic biologic therapy in 2025, with sales of $1.2 billion.

Nucala, administered by a healthcare professional as a 100mg fixed dose subcutaneous injection every 28 days, is offered to healthcare providers through a network of GSK-authorized wholesalers ...

Nucala, which is administered as a once-monthly subcutaneous injection, won its first FDA approval in 2015 as a treatment for severe asthma. The Thursday approval came later than GSK expected.

GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps. First IL-5 therapy approved as an add-on treatment in the US for adults with ...

GlaxoSmithKline PLC’s Nucala therapy has been approved to treat patients with severe asthma attacks in combination with other drugs, the Food and Drug Administration said Wednesday.

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Nucala® (mepolizumab), the first and only biologic add-on therapy for people 12 years and older with severe asthma with an eosinophilic ...